10 Best Low Cost Stocks to Buy According to Billionaires

5. Immunovant, Inc. (NASDAQ:IMVT)

No. of Billionaires: 11

Total Value of Billionaire Holdings: $0.16 Billion

Immunovant, Inc. (NASDAQ:IMVT), based in New York City, is a clinical-stage biopharmaceutical company. The company’s focus is on developing monoclonal antibodies to treat autoimmune diseases. Its lead candidate, IMVT-1402, is designed to inhibit the neonatal Fc receptor (FcRn), aiming to reduce pathogenic IgG antibodies. Competing with Argenx and similar competitors, the company serves the high-need market in autoimmune indications such as myasthenia gravis and Graves’ disease. Its competitive edge lies in differentiated FcRn-targeting biology with strong backing from Roivant Sciences.

Immunovant, Inc. (NASDAQ:IMVT) is backed by 11 billionaires whose collective stake amounts to $0.16 billion. As reported in the fourth quarter, the company’s pro-forma cash balance results in $825 million. This included $450 million in gross proceeds from a private placement closed on January 15, 2025. The company has not provided any guidance for 2025. However, the progress of its lead asset, IMVT-1402, has garnered the market’s attention. Six Investigational New Drug (IND) applications have been cleared for this lead asset, resulting in high expectations for it in 2025.

Immunovant, Inc. (NASDAQ:IMVT) is held by 35 hedge funds at the end of Q4 2024, suggesting notable institutional interest. Rated as a Buy, the stock has a projected upside of 225.79%, higher than all the other entrants on our list.